Trial reportSurgery today2016
Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
Trial report in Surgery today, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis.Updates in surgery · 2024Pooled it
- Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2019Pooled it
- Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.The British journal of surgery · 2018Pooled it
- Trial
- Review
- Advances in neoadjuvant therapy for pancreatic cancer: Current trends and future directions.World journal of clinical oncology · 2025Review
- Review
- Current update of treatment strategies for borderline resectable pancreatic cancer: a narrative review.Journal of gastrointestinal oncology · 2022Review
- Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?Frontiers in oncology · 2022Review
- [Radiologic Evaluation for Resectability of Pancreatic Adenocarcinoma].Taehan Yongsang Uihakhoe chi · 2021Review
- Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer.Frontiers in oncology · 2021Review
- Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis.Journal of clinical medicine · 2020Article
- [EJNMMI research · 2019Article
- Role of histone deacetylase 1 in distant metastasis of pancreatic ductal cancer.Cancer science · 2018Article
- Subgroup analysis reveals molecular heterogeneity and provides potential precise treatment for pancreatic cancers.OncoTargets and therapy · 2018Article
- A novel preoperative predictor of pancreatic fistula using computed tomography after distal pancreatectomy with staple closure.Surgery today · 2017Observational
- Superior mesenteric artery margin in pancreaticoduodenectomy for pancreatic adenocarcinoma.Oncotarget · 2017Article
- Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposesIn the surgical treatment of pancreatic cancer, margin-negative status is one of the most important determinants of survival. We conducted this study to explore surgical margin status as well as other factors affecting the survival of borderline-resectable pancreatic cancer (BRPC) patients who received neoadjuvant chemotherapy with gemcitabine and S-1.
methodsEighteen BRPC patients were prospectively treated with concurrent gemcitabine and S-1 neoadjuvant chemotherapy (NAC+) and 15 of these patients underwent resection. We evaluated the safety and efficacy of this treatment regimen by comparing the outcomes of these patients with those of 19 BRPC patients who did not receive neoadjuvant chemotherapy (NAC-) during the same period.
resultsFifteen (83 %) of the NAC+ patients underwent pancreatectomy. The remaining three patients (17 %) had regional tumor progression or liver metastasis. Of the 15 NAC+ patients who underwent resection, 3 (20 %) had margin-positive status, whereas 9 of the 19 (43 %) NAC- patients had margin-positive status (p = 0.002). However, disease-free survival and overall survival were similar in the two groups (MST 21.7 vs. 21.1 months). NAC+ patients with tumors smaller than 30 mm had favorable overall survival (MST 43.9 vs. 23.1 months, p = 0.0321). Most recurrences developed at distant sites rather than locally in both groups.
conclusionsIn the neoadjuvant setting, gemcitabine and S-1 improved the negative surgical margin rate in BRPC patients, but it did not improve survival. Thus, neoadjuvant chemotherapy should be given to BRPC patients at an earlier stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.